Navigating Treatment Pathways in Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: Optimizing Second-Line Endocrine and Targeted Therapies

J Clin Oncol. 2024 Dec;42(34):4012-4017. doi: 10.1200/JCO-24-01295. Epub 2024 Sep 18.

Abstract

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Antineoplastic Agents, Hormonal / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / pathology
  • Breast Neoplasms* / therapy
  • Female
  • Humans
  • Middle Aged
  • Molecular Targeted Therapy*
  • Receptor, ErbB-2* / metabolism
  • Receptors, Estrogen* / metabolism
  • Receptors, Progesterone / metabolism

Substances

  • Receptor, ErbB-2
  • Receptors, Estrogen
  • ERBB2 protein, human
  • Antineoplastic Agents, Hormonal
  • Receptors, Progesterone